Supplementary File 1: PD1-IL2v Target Receptor Expression in PBMCs and TILs

A 665.4 KB PDF file authored by Amrita Manchala, last updated June 1, 2026. It contains ex-vivo characterization data for the immunocytokine PD1-IL2v (eciskafusp alfa), using matched peripheral blood mononuclear cells (PBMCs) and tumor-infiltrating lymphocytes (TILs) from patients across seven solid tumor types. The study analyzes PD-1 receptor density and the preferential targeting of CD8+ T cell subsets over regulatory T cells.

Use Cases

• Validate PD-1 receptor density as a biomarker for drug activity based on the comparative analysis of PBMCs and TILs.
• Investigate the selective targeting of stem-like and effector CD8+ T cells over Tregs by PD1-IL2v based on ex-vivo assay results.
• Guide patient selection strategies for PD1-IL2v therapy based on findings regarding subset prevalence and PD-1 expression levels.

Strengths

• Data is derived from matched PBMC and TIL samples from patients across seven solid tumor indications.
• Includes specific quantitative findings, such as PD-1 receptor density being increased up to three-fold on CD8+ TILs compared to PBMCs.
• Released under a permissive CC-BY-4.0 license for reuse.

Limitations

• The dataset is a 665.4 KB PDF file; the underlying tabular or raw data is not directly accessible.
• Column-level documentation is absent; field semantics must be inferred from the document text.
• Row count is unknown, which may limit suitability assessment for direct computational analysis.

Provenance

Source

figshare

Collection Method

Ex-vivo characterization assays performed on matched PBMC and TIL samples from CPI-naïve patients.

Freshness

Last updated 2026-06-01 05:18:24; freshness should be verified.